مرکز تحقیقات شیمی دارویی و گیاهی

			Journal Club list
تاریخ	ارائه دهنده	عنوان
1404/02/28	دکتر موسوی	MET on-target resistance.
1404/02/22	دکتر جعفری	Next Generation In Silico Drug Design.
1404/02/08	دکتر پوست فروش	In silico SELEX screening and statistical analysis of newly designed 5mer peptide-aptamers as Bcl-xl inhibitors using the Taguchi.
1404/01/25	دکتر مرتضوی	Targeting HGF/c‑MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion.
1404/07/14	دکتر مرتضوی	Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition.
1403/10/24	دکتر امیدرضا فیروزی	Mapping combinatorial drug effects to DNA damage response kinase inhibitors Hanrui Zhang et al. Nature Comm 2023 (Session 1)
1403/10/17	دکتر امیدرضا فیروزی	Mapping combinatorial drug effects to DNA damage response kinase inhibitors Hanrui Zhang et al. Nature Comm 2023 (Session 2)
1403/05/15	دکتر پگاه مردانه	Design, synthesis, biological evaluation, and structure activity relationships of new derivatives NH-substituted 1,4 Naphthoquinone connected to triazole or acyl hydrazone groups as potential agent for cancer treatment.
1403/04/12	دکتر مرتضوی	PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation.
1403/04/04	دکتر حسنی	Anticancer effect of combination therapy of Olaparib and chemotherapy drugs.
1403/03/22	دکتر سمیه کریمیان	Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells.
1403/02/17	دکتر موسوی	Mesenchymal–epithelial transition and AXL inhibitor TP 0903 sensitize triple negative breast cancer cells to the ‑ ‑antimalarial compound, artesunate.
1403/01/25	دکتر جعفری	SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
1402/11/09	دکتر سمیه کریمیان	Design, Synthesis, and Antitumor Activity of Potent and Selective EGFRL858R/T 790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small Cell Lung Cancer.
1402/10/10	دکتر پوست فروش	Exploring the Various Conformations of ABC Transporters.
1402/10/08	دکتر موسوی	Targeting DNA damage response in pancreatic cancer.
1402/08/08	دکتر موسوی	MDR-related ABC transporters.
1402/08/01	دکتر حسنی	Discussing the possible anticancer pathway of the renin-angiotensin system as well as the anticancer pathway of metformin and sertraline.
1402/07/03	دکتر امیدرضا فیروزی	Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition Concetta D’Ambrosio et al. Int. J. Mol. Sci. 2022. (Session 2)
1402/05/16	دکتر جعفری	p38 MAPK inhibitor SB203580 enhances anticancer activity of PARP inhibitor olaparib in a synergistic way on non- small cell lung carcinoma A549 cell.
1402/05/02	دکتر پگاه مردانه	Design, preparation and biological evaluation of a 177Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors.
1402/04/26	دکتر نظری	In Vivo Bioluminescent Imaging (BLI)
1402/04/03	دکتر امیدرضا فیروزی	Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition Concetta D’Ambrosio et al. Int. J. Mol. Sci. 2022. (Session 1)
1402/04/03	دکتر امیدرضا فیروزی	Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition Concetta D’Ambrosio et al. Int. J. Mol. Sci. 2022. (Session 1)
1402/03/29	دکتر پوست فروش	Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer.
1402/03/22	دکتر پگاه مردانه	Kinase drug discovery 20 years after imatinib: progress and future directions.
1402/03/01	دکتر نظری	Blockade of c-Met-Mediated Signaling Pathways by E7050 Suppresses Growth and Promotes Apoptosis in Multidrug- Resistant Human Uterine Sarcoma Cells.
1402/02/05	دکتر پگاه مردانه	Design, preparation and biological evaluation of a 177Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors.
1401/12/15	دکتر حسنی	Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma.
1401/11/17	دکتر امیدرضا فیروزی	Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use Rachel Abbotts et al. Cancers 2022. (Session 2)
1401/10/26	دکتر امیدرضا فیروزی	Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use Rachel Abbotts et al. Cancers 2022. (Session 1)
1401/10/05	دکتر مرتضوی	Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial Mesenchymal Transition to Promote Cancer Progression.
1401/10/05	دکتر مرتضوی	Targeting the HGF/MET pathway in advanced pancreatic cancer.
1401/08/16	دکتر موسوی	Dual mechanisms of action of PARP inhibitors: PARylation inhibition and trapping of PARP-DNA complexes (PARP trapping)
1401/05/25	دکتر نظری	Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma.
1401/04/21	دکتر مرتضوی	Network pharmacology (3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway)
1401/04/17	دکتر امیدرضا فیروزی	DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives Jojanneke Stoof et al. Front. Cell Dev. Biol. 2021. (Session 2)
1401/04/07	دکتر امیدرضا فیروزی	DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives Jojanneke Stoof et al. Front. Cell Dev. Biol. 2021. (Session 2)
1401/03/24	دکتر امیدرضا فیروزی	DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives Jojanneke Stoof et al. Front. Cell Dev. Biol. 2021. (Session 1)
1401/02/06	دکتر نظری	Synergistic anti-cancer action of salicylic acid and cisplatin on HeLa cells elucidated by network pharmacology and in vitro analysis.
1400/07/26	دکتر نظری	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells.
1400/11/25	دکتر امیدرضا فیروزی	DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives Lukas Perkhofer et al. Gut 2021.(Session 1)
1400/12/09	دکتر امیدرضا فیروزی	DNA damage repair as a target in pancreatic cancer: state-of the-art and future perspectives Lukas Perkhofer et al. Gut 2021. (Session 2)
1400/08/10	دکتر موسوی	Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines.
1400/02/11	دکتر موسوی	Host-dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.
1397/10/25	دکتر موسوی	Targeting MET in cancer: Combination therapies.
1397/04/11	دکتر موسوی	Kinase as attractive targets of cancer therapy.
1398/01/28	دکتر مرتضوی	Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion.
1398/08/13	دکتر مرتضوی	Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
1399/09/19	دکتر امیدرضا فیروزی	A landscape of pharmacogenomic Interactions in cancer.
1399/07	دکتر مرتضوی	Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway.
1399/10/01	دکتر نظری	Combine and conquer: challenges for targeted therapy combinations in early phase trials.
1399/10/17	دکتر مرتضوی	Pancreatic cancer
1399/08/01	دکتر موسوی	Drug combination database.